China's active pharmaceutical ingredient (API) industry maintained its recovery momentum in 2025, with H1 revenue rising 1.5% year-on-year and profits increasing 5.6%. The sector's annual revenue reached 424.15 billion yuan in 2024. Import-export trade delivered strong performance, with total trade volume hitting $41.545 billion from January to September, up 4.7% YoY. Exports totaled $32.381 billion while imports stood at $9.165 billion, marking a gradual easing of the two-year "volume-for-price" strategy. Asia and Europe remained dominant export markets, jointly accounting for 74% of total exports. Vitamin APIs led the export surge with a 34.8% growth in sales value.
Core Data Charts
Indicators | Value / Growth Rate | Supplementary notes |
2024 Annual industry revenue scale | 4241.5 Billion yuan | Adjustment period concludes with growth rate turning positive to 0.3% |
2025 Revenue growth rate in the first half of the year | 1.5% | Industry recovery trend continues |
2025 Profit growth in the first half of the year | 5.6% | Profitability steadily improves |
2025 Year1-9 Total Import and Export Volume by Month | 415.45 USD billion | Year-on-year growth 4.7% |
2025 Year1-9 Monthly Export Volume | 323.81 USD billion | Year-on-year growth 2.23%Prices Rise Year-on-Year0.5% |
2025 Year1-9 Monthly Import Volume | 91.65 USD billion | Significant Year-on-Year Growth 14.49% |
Share of Major Export Markets | 74% | Asia + Total Share of Europe |
Growth Rate of Vitamin Exports | 34.8% | Growth Driven by Unrestored Overseas Production Capacity |